Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

Inclusion Criteria: * Patients who have completed the entire treatment period of the 28-week core study * Patients must be able to understand and communicate with the investigator and comply with the requirements for the study and must give a written, signed, and dated informed consent before study treatment in the extension study Exclusion Criteria: * Inability or unwillingness to undergo repeated subcutaneous injections * Inability to comply with study or follow-up procedures * Any medical or psychiatric condition which, in the investigator's opinion would preclude the participant from adhering to the protocol or completing the study per protocol * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/mL) * Women of childbearing potential (WoCBP), defined as all women physiologically capable of becoming pregnant, UNLESS * They are using simultaneously double barrier or two acceptable methods of contraception * They are postmenopausal with an appropriate clinical profile and had no regular menstrual bleeding for at least twelve (12) months prior to initial dosing * They have undergone reliable surgical sterilization at least six (6) months prior to initial dosing * Their career, lifestyle, or sexual orientation precludes intercourse with a male partner * Partners have been sterilized by vasectomy or other reliable means Other protocol-defined inclusion/exclusion criteria may apply